-
公开(公告)号:US20100168065A1
公开(公告)日:2010-07-01
申请号:US12529142
申请日:2008-03-07
申请人: Jorge Eduardo Vialard , Patrick René Angibaud , Laurence Anne Mevellec , Christophe Meyer , Eddy Jean Edgard Freyne , Isabelle Noëlle Pilatte , Bruno Roux , Elisabeth Thérèse Jeanne Pasquier , Xavier Marc Bourdrez , Christophe Denis Adelinet , Laurence Francoise Bernadette Marconnet-Decrane , Jacqueline Anne Macritchie , James Edward Stewart Duffy , Andrew Pate Owens , Pierre-Henri Storck , Virginie Sophie Poncelet
发明人: Jorge Eduardo Vialard , Patrick René Angibaud , Laurence Anne Mevellec , Christophe Meyer , Eddy Jean Edgard Freyne , Isabelle Noëlle Pilatte , Bruno Roux , Elisabeth Thérèse Jeanne Pasquier , Xavier Marc Bourdrez , Christophe Denis Adelinet , Laurence Francoise Bernadette Marconnet-Decrane , Jacqueline Anne Macritchie , James Edward Stewart Duffy , Andrew Pate Owens , Pierre-Henri Storck , Virginie Sophie Poncelet
IPC分类号: A61K31/675 , C07D215/227 , A61K31/4704 , C07D413/12 , A61K31/5377 , C07D401/12 , A61K31/496 , A61K31/506 , C07F9/38 , A61K31/502 , A61K31/498 , C07D471/04 , A61K31/437 , A61P35/00
CPC分类号: C07D215/227 , C07D401/06 , C07D401/12 , C07D405/06 , C07D409/06 , C07D413/06 , C07D417/06
摘要: The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, n, m and X have defined meanings.
摘要翻译: 本发明提供式(I)化合物,它们作为PARP抑制剂的用途以及包含所述式(I)化合物的药物组合物,其中R1,R2,R3,R4,R5,R6,R7,n,m和X具有 定义含义。
-
公开(公告)号:US08299256B2
公开(公告)日:2012-10-30
申请号:US12529142
申请日:2008-03-07
申请人: Jorge Eduardo Vialard , Patrick René Angibaud , Laurence Anne Mevellec , Christophe Meyer , Eddy Jean Edgard Freyne , Isabelle Noëlle Constance Pilatte , Bruno Roux , Elisabeth Thérèse Jeanne Pasquier , Xavier Marc Bourdrez , Christophe Denis Adelinet , Laurence Françoise Bernadette Marconnet-Decrane , Jacqueline Anne Macritchie , James Edward Stewart Duffy , Andrew Pate Owens , Pierre-Henri Storck , Virginie Sophie Poncelet
发明人: Jorge Eduardo Vialard , Patrick René Angibaud , Laurence Anne Mevellec , Christophe Meyer , Eddy Jean Edgard Freyne , Isabelle Noëlle Constance Pilatte , Bruno Roux , Elisabeth Thérèse Jeanne Pasquier , Xavier Marc Bourdrez , Christophe Denis Adelinet , Laurence Françoise Bernadette Marconnet-Decrane , Jacqueline Anne Macritchie , James Edward Stewart Duffy , Andrew Pate Owens , Pierre-Henri Storck , Virginie Sophie Poncelet
IPC分类号: C07D215/38
CPC分类号: C07D215/227 , C07D401/06 , C07D401/12 , C07D405/06 , C07D409/06 , C07D413/06 , C07D417/06
摘要: The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, n, m and X have defined meanings.
摘要翻译: 本发明提供式(I)化合物,它们作为PARP抑制剂的用途以及包含所述式(I)化合物的药物组合物,其中R1,R2,R3,R4,R5,R6,R7,n,m和X具有 定义含义。
-
公开(公告)号:US08778966B2
公开(公告)日:2014-07-15
申请号:US13617686
申请日:2012-09-14
申请人: Jorge Eduardo Vialard , Patrick René Angibaud , Laurence Anne Mevellec , Christophe Meyer , Eddy Jean Edgard Freyne , Isabelle Noëlle Constance Pilatte , Bruno Roux , Elisabeth Thèrése Jeanne Pasquier , Xavier Marc Bourdrez , Christophe Denis Adelinet , Laurence Françoise Bernadette Marconnet-Decrane , Jacqueline Anne Macritchie , James Edward Stewart Duffy , Andrew Pate Owens , Pierre-Henri Storck , Virginie Sophie Poncelet
发明人: Jorge Eduardo Vialard , Patrick René Angibaud , Laurence Anne Mevellec , Christophe Meyer , Eddy Jean Edgard Freyne , Isabelle Noëlle Constance Pilatte , Bruno Roux , Elisabeth Thèrése Jeanne Pasquier , Xavier Marc Bourdrez , Christophe Denis Adelinet , Laurence Françoise Bernadette Marconnet-Decrane , Jacqueline Anne Macritchie , James Edward Stewart Duffy , Andrew Pate Owens , Pierre-Henri Storck , Virginie Sophie Poncelet
IPC分类号: A61K31/04 , C07D413/06 , C07D401/06 , C07D401/12 , C07D405/06 , C07D409/06 , C07D215/227 , C07D417/06
CPC分类号: C07D215/227 , C07D401/06 , C07D401/12 , C07D405/06 , C07D409/06 , C07D413/06 , C07D417/06
摘要: The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, n, m and X have defined meanings.
摘要翻译: 本发明提供式(I)化合物,它们作为PARP抑制剂的用途以及包含所述式(I)化合物的药物组合物,其中R1,R2,R3,R4,R5,R6,R7,n,m和X具有 定义含义。
-
公开(公告)号:US20110028433A1
公开(公告)日:2011-02-03
申请号:US12934733
申请日:2009-03-26
申请人: Eddy Jean Edgard Freyne , Laurence Anne Mevellec , Jorge Eduardo Vialard , Christophe Meyer , Elisabeth Thérèse Jeanne Pasquier , Xavier Marc Bourdrez , Patrick René Angibaud
发明人: Eddy Jean Edgard Freyne , Laurence Anne Mevellec , Jorge Eduardo Vialard , Christophe Meyer , Elisabeth Thérèse Jeanne Pasquier , Xavier Marc Bourdrez , Patrick René Angibaud
IPC分类号: A61K31/517 , C07D403/06 , C07D239/80 , C07F7/10 , C07D401/06 , A61K31/695 , C07D417/06 , A61P35/00
CPC分类号: C07D239/80 , C07D401/06 , C07D417/06
摘要: The present invention provides compounds of formula (I), their use as inhibitors of tubulin polymerization as well as pharmaceutical compositions comprising said compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, n, m and X have defined meanings.
摘要翻译: 本发明提供式(I)化合物,其作为微管蛋白聚合抑制剂的用途以及包含所述式(I)化合物的药物组合物,其中R1,R2,R3,R4,R5,R6,n,m和X具有 定义含义。
-
公开(公告)号:US08168644B2
公开(公告)日:2012-05-01
申请号:US12934733
申请日:2009-03-26
申请人: Eddy Jean Edgard Freyne , Laurence Anne Mevellec , Jorge Eduardo Vialard , Christophe Meyer , Elisabeth Thérèse Jeanne Pasquier , Xavier Marc Bourdrez , Patrick René Angibaud
发明人: Eddy Jean Edgard Freyne , Laurence Anne Mevellec , Jorge Eduardo Vialard , Christophe Meyer , Elisabeth Thérèse Jeanne Pasquier , Xavier Marc Bourdrez , Patrick René Angibaud
IPC分类号: A01N43/54 , A61K31/517 , C07D239/72
CPC分类号: C07D239/80 , C07D401/06 , C07D417/06
摘要: The present invention provides compounds of formula (I), their use as inhibitors of tubulin polymerization as well as pharmaceutical compositions comprising said compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, n, m and X have defined meanings.
摘要翻译: 本发明提供式(I)化合物,其作为微管蛋白聚合抑制剂的用途以及包含所述式(I)化合物的药物组合物,其中R1,R2,R3,R4,R5,R6,n,m和X具有 定义含义。
-
公开(公告)号:US06914066B2
公开(公告)日:2005-07-05
申请号:US10179444
申请日:2002-06-24
IPC分类号: C07D215/06 , A61K31/4365 , A61K31/4709 , A61K31/4745 , A61K31/498 , A61K31/519 , A61P35/00 , C07D215/18 , C07D401/06 , C07D403/06 , C07D471/04 , C07D487/04 , A61K31/435 , A61K31/517
CPC分类号: C07D401/06 , A61K31/4745 , A61K31/498 , A61K31/519 , C07D403/06 , C07D471/04 , C07D487/04
摘要: This invention concerns compounds of formula the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein ═X1—X2—X3— is a trivalent radical,; >Y1—Y2— is a trivalent radical; r and s are each independently 0, 1, 2, 3, 4 or 5; t is 0, 1, 2 or 3; each R1 and R2 are independently hydroxy, halo, cyano, C1-6alkyl, trihalomethyl, trihalomethoxy, C2-6alkenyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkylthio, C1-6alkyloxyC1-6alkyloxy, C1-6alkyloxycarbonyl, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)amino, mono- or di(C1-6alkylaminoC1-6alkyloxy, aryl, arylC1-6alkyl, aryloxy or arylC1-6alkyloxy, hydroxycarbonyl, C1-6alkyloxycarbonyl; or two R1 or R2 on adjacent positions form together a bivalent radical; R3 is hydrogen, halo, C1-6alkyl, cyano, haloC1-6alkyl, hydroxyC1-6alkyl, cyanoC1-6alkyl, aminoC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkylthio-C1-6alkyl, aminocarbonylC1-6alkyl, hydroxycarbonyl, hydroxycarbonylC1-6alkyl, C1-6alkyoxycarbonylC1-6alkyl, C1-6alkylcarbonylC1-6alkyl, C1-6alkyloxycarbonyl, aryl, arylC1-6alkyloxyC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, or a radical of formula —O—R10, —S—R10 or —NR11R12; R4 is an optionally substituted imidazolyl; aryl is an optionally substituted phenyl or naphthalenyl; having farnesyl transferase and geranylgeranyl transferase inhibiting activity; their preparation, compositions containing them and their use as a medicine.
-
公开(公告)号:US06458800B1
公开(公告)日:2002-10-01
申请号:US09868992
申请日:2001-08-29
IPC分类号: C07D47104
CPC分类号: C07D401/06 , A61K31/4745 , A61K31/498 , A61K31/519 , C07D403/06 , C07D471/04 , C07D487/04
摘要: This invention concerns compounds of formula the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein ═X1—X2—X3— is a trivalent radical,; >Y1—Y2— is a trivalent radical; r and s are each independently 0, 1, 2, 3, 4 or 5; t is 0, 1, 2 or 3; each R1 and R2 are independently hydroxy, halo, cyano, C1-6alkyl, trihalomethyl, trihalomethoxy, C2-6alkenyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkylthio, C1-6alkyloxyC1-6alkyloxy, C1-6alkyloxycarbonyl, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)amino, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, aryl, arylC1-6alkyl, aryloxy or arylC1-6alkyloxy, hydroxycarbonyl, C1-6alkyloxycarbonyl; or two R1 or R2 on adjacent positions form together a bivalent radical; R3 is hydrogen, halo, C1-6alkyl, cyano, haloC1-6alkyl, hydroxyC1-6alkyl, cyanoC1-6alkyl, aminoC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkylthio-C1-6alkyl, aminocarbonylC1-6alkyl, hydroxycarbonyl, hydroxycarbonylC1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, C1-6alkylcarbonylC1-6alkyl, C1-6alkyloxycarbonyl, aryl, arylC1-6alkyloxyC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, or a radical of formula —O—R10, —S—R10 or —NR11R12; R4 is an optionally substituted imidazolyl; aryl is an optionally substituted phenyl or naphthalenyl; having farnesyl transferase and geranylgeranyl transferase inhibiting activity; their preparation, compositions containing them and their use as a medicine.
摘要翻译: 本发明涉及配制药学上可接受的酸加成盐和其立体化学异构形式的化合物,其中= X 1 -X 2 -X 3 - 是三价基团; Y1-Y2-是三价基; r和s各自独立地为0,1,2,3,4或5; t为0,1,2或3; 每个R 1和R 2独立地是羟基,卤素,氰基,C 1-6烷基,三卤甲基,三卤甲氧基,C 2-6烯基,C 1-6烷氧基,羟基C 1-6烷氧基,C 1-6烷硫基,C 1-6烷氧基C 1-6烷氧基,C 1-6烷氧基羰基,氨基C 1-6烷氧基, 单或二(C 1-6烷基)氨基,单或二(C 1-6烷基)氨基C 1-6烷氧基,芳基,芳基C 1-6烷基,芳氧基或芳基C 1-6烷氧基,羟基羰基,C 1-6烷氧基羰基; 或相邻位置上的两个R1或R2一起形成二价基团; R 3是氢,卤素,C 1-6烷基,氰基,卤代C 1-6烷基,羟基C 1-6烷基,氰基C 1-6烷基,氨基C 1-6烷基,C 1-6烷氧基C 1-6烷基,C 1-6烷硫基-C 1-6烷基,氨基羰基C 1-6烷基,羟基羰基,羟基羰基C1- C 1-6烷氧基羰基C 1-6烷基,C 1-6烷基羰基C 1-6烷基,C 1-6烷氧基羰基,芳基,芳基C 1-6烷氧基C 1-6烷基,一或二(C 1-6烷基)氨基C 1-6烷基,或式-O-R 10基团, S-R10或-NR11R12; R4是任选取代的咪唑基; 芳基是任选取代的苯基或萘基; 具有法呢基转移酶和香叶基香叶基转移酶抑制活性; 其制剂,含有它们的组合物及其作为药物的用途。
-
-
-
-
-
-